Windtree Announces Istaroxime has been Chosen for a Plenary Session Presentation at the Heart Failure Society of America 2025

Core Insights - Windtree Therapeutics is advancing istaroxime for treating SCAI Stage C cardiogenic shock, with interim data showing promising safety and efficacy [1][2][3] - Istaroxime has the potential to improve cardiac function and increase blood pressure without raising heart rate, addressing a significant unmet need in acute decompensated heart failure [2][3] Company Overview - Windtree Therapeutics is a diversified company with multiple divisions, including a cryptocurrency treasury strategy and two therapeutic pipelines [4] Product Details - Istaroxime is a first-in-class dual-mechanism therapy that enhances both systolic and diastolic cardiac function, showing significant improvements in cardiac function and blood pressure in previous studies [3]